Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy

Background The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of gastroenterology 2012-12, Vol.47 (12), p.1323-1335
Hauptverfasser: Kondo, Yasuteru, Ueno, Yoshiyuki, Ninomiya, Masashi, Tamai, Keiichi, Tanaka, Yasuhito, Inoue, Jun, Kakazu, Eiji, Kobayashi, Koju, Kimura, Osamu, Miura, Masahito, Yamamoto, Takeshi, Kobayashi, Tomoo, Igarashi, Takehiko, Shimosegawa, Tooru
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1335
container_issue 12
container_start_page 1323
container_title Journal of gastroenterology
container_volume 47
creator Kondo, Yasuteru
Ueno, Yoshiyuki
Ninomiya, Masashi
Tamai, Keiichi
Tanaka, Yasuhito
Inoue, Jun
Kakazu, Eiji
Kobayashi, Koju
Kimura, Osamu
Miura, Masahito
Yamamoto, Takeshi
Kobayashi, Tomoo
Igarashi, Takehiko
Shimosegawa, Tooru
description Background The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy. Methods One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV. Results Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-γ-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-γ-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-γ-secreting cells were also increased during Peg-IFN/RBV-therapy. Conclusion The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.
doi_str_mv 10.1007/s00535-012-0596-x
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1439235844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714584946</galeid><sourcerecordid>A714584946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c624t-c5a86e9979967d2966e29a18d9a3f88627bbf454cd5e9c71bcbe07636b3d5fb43</originalsourceid><addsrcrecordid>eNp1kUFr3DAUhEVoSTZpf0AvxdBLL8pKsiRbx2RpsoGQlqTdU0HI8vNWwbZcyYbsv6_MpklaWnQQenwzvNEg9I6SU0pIsYyEiFxgQhkmQkn8cIAWlKeJUIy9QguiOMeUFvwIHcd4TwjNiSgP0RFjoiwZlwv0_Q5-TtCPzrSZ67qp963fOptepjftLrqY-SZbn2-W69Umsx67vgE7Qp0NZnRJGLN6Cq7fZl9gi68ubpa355ts_AHBDLs36HVj2ghvH-8T9O3i09fVGl9_vrxanV1jKxkfsRWmlKBUoZQsaqakBKYMLWtl8qYsJSuqquGC21qAsgWtbAWkkLms8lo0Fc9P0Me97xB8ShNH3blooW1ND36KOv2JYrko-Yx--Au991NIURPFpBRyJp-prWlBp8h-DMbOpvqsoDw5KS4TdfoPKp0aOmd9D41L8z8EdC-wwccYoNFDcJ0JO02JnhvV-0Z1alTPjeqHpHn_uPBUdVA_KX5XmAC2B-Iw9wDhRaL_uv4CGsypKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1266563923</pqid></control><display><type>article</type><title>Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Kondo, Yasuteru ; Ueno, Yoshiyuki ; Ninomiya, Masashi ; Tamai, Keiichi ; Tanaka, Yasuhito ; Inoue, Jun ; Kakazu, Eiji ; Kobayashi, Koju ; Kimura, Osamu ; Miura, Masahito ; Yamamoto, Takeshi ; Kobayashi, Tomoo ; Igarashi, Takehiko ; Shimosegawa, Tooru</creator><creatorcontrib>Kondo, Yasuteru ; Ueno, Yoshiyuki ; Ninomiya, Masashi ; Tamai, Keiichi ; Tanaka, Yasuhito ; Inoue, Jun ; Kakazu, Eiji ; Kobayashi, Koju ; Kimura, Osamu ; Miura, Masahito ; Yamamoto, Takeshi ; Kobayashi, Tomoo ; Igarashi, Takehiko ; Shimosegawa, Tooru</creatorcontrib><description>Background The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy. Methods One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV. Results Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-γ-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-γ-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-γ-secreting cells were also increased during Peg-IFN/RBV-therapy. Conclusion The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.</description><identifier>ISSN: 0944-1174</identifier><identifier>EISSN: 1435-5922</identifier><identifier>DOI: 10.1007/s00535-012-0596-x</identifier><identifier>PMID: 22588246</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Abdominal Surgery ; Adult ; Amino Acid Sequence ; Analysis ; Antiviral Agents - therapeutic use ; Biliary Tract ; Care and treatment ; Case-Control Studies ; CD4 antigen ; CD4-Positive T-Lymphocytes - drug effects ; CD4-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - drug effects ; CD8-Positive T-Lymphocytes - immunology ; Cells, Cultured ; Coinfection - drug therapy ; Coinfection - immunology ; Colorectal Surgery ; Comorbidity ; Drug Therapy, Combination ; Gastroenterology ; Health aspects ; Hepacivirus - genetics ; Hepacivirus - isolation &amp; purification ; Hepatitis B ; Hepatitis B virus ; Hepatitis B virus - genetics ; Hepatitis B virus - isolation &amp; purification ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - immunology ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - immunology ; Hepatology ; Humans ; Immunity, Cellular - drug effects ; Infection ; Interferon ; Interferon-alpha - therapeutic use ; Interferon-gamma - biosynthesis ; Lymphocyte Activation - drug effects ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Original Article—Liver ; Pancreas ; Polyethylene Glycols - therapeutic use ; Recombinant Proteins - therapeutic use ; Ribavirin - therapeutic use ; RNA ; Surgical Oncology ; T cells</subject><ispartof>Journal of gastroenterology, 2012-12, Vol.47 (12), p.1323-1335</ispartof><rights>Springer 2012</rights><rights>COPYRIGHT 2012 Springer</rights><rights>Springer Japan 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c624t-c5a86e9979967d2966e29a18d9a3f88627bbf454cd5e9c71bcbe07636b3d5fb43</citedby><cites>FETCH-LOGICAL-c624t-c5a86e9979967d2966e29a18d9a3f88627bbf454cd5e9c71bcbe07636b3d5fb43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00535-012-0596-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00535-012-0596-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22588246$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kondo, Yasuteru</creatorcontrib><creatorcontrib>Ueno, Yoshiyuki</creatorcontrib><creatorcontrib>Ninomiya, Masashi</creatorcontrib><creatorcontrib>Tamai, Keiichi</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><creatorcontrib>Inoue, Jun</creatorcontrib><creatorcontrib>Kakazu, Eiji</creatorcontrib><creatorcontrib>Kobayashi, Koju</creatorcontrib><creatorcontrib>Kimura, Osamu</creatorcontrib><creatorcontrib>Miura, Masahito</creatorcontrib><creatorcontrib>Yamamoto, Takeshi</creatorcontrib><creatorcontrib>Kobayashi, Tomoo</creatorcontrib><creatorcontrib>Igarashi, Takehiko</creatorcontrib><creatorcontrib>Shimosegawa, Tooru</creatorcontrib><title>Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy</title><title>Journal of gastroenterology</title><addtitle>J Gastroenterol</addtitle><addtitle>J Gastroenterol</addtitle><description>Background The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy. Methods One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV. Results Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-γ-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-γ-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-γ-secreting cells were also increased during Peg-IFN/RBV-therapy. Conclusion The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.</description><subject>Abdominal Surgery</subject><subject>Adult</subject><subject>Amino Acid Sequence</subject><subject>Analysis</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biliary Tract</subject><subject>Care and treatment</subject><subject>Case-Control Studies</subject><subject>CD4 antigen</subject><subject>CD4-Positive T-Lymphocytes - drug effects</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - drug effects</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cells, Cultured</subject><subject>Coinfection - drug therapy</subject><subject>Coinfection - immunology</subject><subject>Colorectal Surgery</subject><subject>Comorbidity</subject><subject>Drug Therapy, Combination</subject><subject>Gastroenterology</subject><subject>Health aspects</subject><subject>Hepacivirus - genetics</subject><subject>Hepacivirus - isolation &amp; purification</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B virus - isolation &amp; purification</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - immunology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Immunity, Cellular - drug effects</subject><subject>Infection</subject><subject>Interferon</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Original Article—Liver</subject><subject>Pancreas</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Ribavirin - therapeutic use</subject><subject>RNA</subject><subject>Surgical Oncology</subject><subject>T cells</subject><issn>0944-1174</issn><issn>1435-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kUFr3DAUhEVoSTZpf0AvxdBLL8pKsiRbx2RpsoGQlqTdU0HI8vNWwbZcyYbsv6_MpklaWnQQenwzvNEg9I6SU0pIsYyEiFxgQhkmQkn8cIAWlKeJUIy9QguiOMeUFvwIHcd4TwjNiSgP0RFjoiwZlwv0_Q5-TtCPzrSZ67qp963fOptepjftLrqY-SZbn2-W69Umsx67vgE7Qp0NZnRJGLN6Cq7fZl9gi68ubpa355ts_AHBDLs36HVj2ghvH-8T9O3i09fVGl9_vrxanV1jKxkfsRWmlKBUoZQsaqakBKYMLWtl8qYsJSuqquGC21qAsgWtbAWkkLms8lo0Fc9P0Me97xB8ShNH3blooW1ND36KOv2JYrko-Yx--Au991NIURPFpBRyJp-prWlBp8h-DMbOpvqsoDw5KS4TdfoPKp0aOmd9D41L8z8EdC-wwccYoNFDcJ0JO02JnhvV-0Z1alTPjeqHpHn_uPBUdVA_KX5XmAC2B-Iw9wDhRaL_uv4CGsypKQ</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Kondo, Yasuteru</creator><creator>Ueno, Yoshiyuki</creator><creator>Ninomiya, Masashi</creator><creator>Tamai, Keiichi</creator><creator>Tanaka, Yasuhito</creator><creator>Inoue, Jun</creator><creator>Kakazu, Eiji</creator><creator>Kobayashi, Koju</creator><creator>Kimura, Osamu</creator><creator>Miura, Masahito</creator><creator>Yamamoto, Takeshi</creator><creator>Kobayashi, Tomoo</creator><creator>Igarashi, Takehiko</creator><creator>Shimosegawa, Tooru</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope></search><sort><creationdate>20121201</creationdate><title>Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy</title><author>Kondo, Yasuteru ; Ueno, Yoshiyuki ; Ninomiya, Masashi ; Tamai, Keiichi ; Tanaka, Yasuhito ; Inoue, Jun ; Kakazu, Eiji ; Kobayashi, Koju ; Kimura, Osamu ; Miura, Masahito ; Yamamoto, Takeshi ; Kobayashi, Tomoo ; Igarashi, Takehiko ; Shimosegawa, Tooru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c624t-c5a86e9979967d2966e29a18d9a3f88627bbf454cd5e9c71bcbe07636b3d5fb43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abdominal Surgery</topic><topic>Adult</topic><topic>Amino Acid Sequence</topic><topic>Analysis</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biliary Tract</topic><topic>Care and treatment</topic><topic>Case-Control Studies</topic><topic>CD4 antigen</topic><topic>CD4-Positive T-Lymphocytes - drug effects</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - drug effects</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cells, Cultured</topic><topic>Coinfection - drug therapy</topic><topic>Coinfection - immunology</topic><topic>Colorectal Surgery</topic><topic>Comorbidity</topic><topic>Drug Therapy, Combination</topic><topic>Gastroenterology</topic><topic>Health aspects</topic><topic>Hepacivirus - genetics</topic><topic>Hepacivirus - isolation &amp; purification</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B virus - isolation &amp; purification</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - immunology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Immunity, Cellular - drug effects</topic><topic>Infection</topic><topic>Interferon</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Original Article—Liver</topic><topic>Pancreas</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Ribavirin - therapeutic use</topic><topic>RNA</topic><topic>Surgical Oncology</topic><topic>T cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kondo, Yasuteru</creatorcontrib><creatorcontrib>Ueno, Yoshiyuki</creatorcontrib><creatorcontrib>Ninomiya, Masashi</creatorcontrib><creatorcontrib>Tamai, Keiichi</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><creatorcontrib>Inoue, Jun</creatorcontrib><creatorcontrib>Kakazu, Eiji</creatorcontrib><creatorcontrib>Kobayashi, Koju</creatorcontrib><creatorcontrib>Kimura, Osamu</creatorcontrib><creatorcontrib>Miura, Masahito</creatorcontrib><creatorcontrib>Yamamoto, Takeshi</creatorcontrib><creatorcontrib>Kobayashi, Tomoo</creatorcontrib><creatorcontrib>Igarashi, Takehiko</creatorcontrib><creatorcontrib>Shimosegawa, Tooru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kondo, Yasuteru</au><au>Ueno, Yoshiyuki</au><au>Ninomiya, Masashi</au><au>Tamai, Keiichi</au><au>Tanaka, Yasuhito</au><au>Inoue, Jun</au><au>Kakazu, Eiji</au><au>Kobayashi, Koju</au><au>Kimura, Osamu</au><au>Miura, Masahito</au><au>Yamamoto, Takeshi</au><au>Kobayashi, Tomoo</au><au>Igarashi, Takehiko</au><au>Shimosegawa, Tooru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy</atitle><jtitle>Journal of gastroenterology</jtitle><stitle>J Gastroenterol</stitle><addtitle>J Gastroenterol</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>47</volume><issue>12</issue><spage>1323</spage><epage>1335</epage><pages>1323-1335</pages><issn>0944-1174</issn><eissn>1435-5922</eissn><abstract>Background The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy. Methods One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV. Results Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-γ-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-γ-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-γ-secreting cells were also increased during Peg-IFN/RBV-therapy. Conclusion The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>22588246</pmid><doi>10.1007/s00535-012-0596-x</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0944-1174
ispartof Journal of gastroenterology, 2012-12, Vol.47 (12), p.1323-1335
issn 0944-1174
1435-5922
language eng
recordid cdi_proquest_miscellaneous_1439235844
source MEDLINE; SpringerLink Journals
subjects Abdominal Surgery
Adult
Amino Acid Sequence
Analysis
Antiviral Agents - therapeutic use
Biliary Tract
Care and treatment
Case-Control Studies
CD4 antigen
CD4-Positive T-Lymphocytes - drug effects
CD4-Positive T-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - drug effects
CD8-Positive T-Lymphocytes - immunology
Cells, Cultured
Coinfection - drug therapy
Coinfection - immunology
Colorectal Surgery
Comorbidity
Drug Therapy, Combination
Gastroenterology
Health aspects
Hepacivirus - genetics
Hepacivirus - isolation & purification
Hepatitis B
Hepatitis B virus
Hepatitis B virus - genetics
Hepatitis B virus - isolation & purification
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - immunology
Hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - immunology
Hepatology
Humans
Immunity, Cellular - drug effects
Infection
Interferon
Interferon-alpha - therapeutic use
Interferon-gamma - biosynthesis
Lymphocyte Activation - drug effects
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article—Liver
Pancreas
Polyethylene Glycols - therapeutic use
Recombinant Proteins - therapeutic use
Ribavirin - therapeutic use
RNA
Surgical Oncology
T cells
title Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T07%3A06%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequential%20immunological%20analysis%20of%20HBV/HCV%20co-infected%20patients%20during%20Peg-IFN/RBV%20therapy&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Kondo,%20Yasuteru&rft.date=2012-12-01&rft.volume=47&rft.issue=12&rft.spage=1323&rft.epage=1335&rft.pages=1323-1335&rft.issn=0944-1174&rft.eissn=1435-5922&rft_id=info:doi/10.1007/s00535-012-0596-x&rft_dat=%3Cgale_proqu%3EA714584946%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1266563923&rft_id=info:pmid/22588246&rft_galeid=A714584946&rfr_iscdi=true